Replies to post #2530 on Gilead Sciences Inc (GILD)

[DewDiligence]

Doubtful, IMO. CYDY’s PRO 140, at best, addresses a small slice of the HIV market that is already served by PFE’s Selzentry, a commercial flop. Please see #msg-45768251 for background info.